Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease

被引:44
|
作者
Venkataraman, Ashwin V. [1 ,2 ]
Mansur, Ayla [3 ]
Rizzo, Gaia [1 ,3 ]
Bishop, Courtney [3 ]
Lewis, Yvonne [3 ]
Kocagoncu, Ece [4 ]
Lingford-Hughes, Anne [1 ]
Huiban, Mickael [3 ]
Passchier, Jan [3 ]
Rowe, James B. [4 ]
Tsukada, Hideo [5 ]
Brooks, David J. [6 ,7 ]
Martarello, Laurent [8 ]
Comley, Robert A. [9 ]
Chen, Laigao [10 ]
Schwarz, Adam J. [11 ]
Hargreaves, Richard [12 ]
Gunn, Roger N. [1 ,3 ]
Rabiner, Eugenii A. [3 ,13 ]
Matthews, Paul M. [1 ,2 ]
机构
[1] Imperial Coll London, Dept Brain Sci, London W12 0NN, England
[2] Imperial Coll London, UK Dementia Res Inst, London W12 0NN, England
[3] Invicro LLC, London W12 0NN, England
[4] Univ Cambridge, Cambridge CB2 2QQ, England
[5] Hamamatsu Photon KK, Hamamatsu, Shizuoka 4348601, Japan
[6] Newcastle Univ, Newcastle NE2 4HH, England
[7] Aarhus Univ, Dept Clin Med, DK-8200 Aarhus, Denmark
[8] Biogen, Cambridge, MA 02142 USA
[9] AbbVie, N Chicago, IL USA
[10] Pfizer Inc, Cambridge, MA 02139 USA
[11] Takeda Pharmaceut Ltd, Cambridge, MA 02139 USA
[12] Bristol Myers Squibb, Princeton, NJ 08543 USA
[13] Kings Coll London, London SE5 8AF, England
基金
英国医学研究理事会;
关键词
IN-VIVO EVALUATION; POSITRON-EMISSION-TOMOGRAPHY; OXIDATIVE STRESS; AMYLOID DEPOSITION; RECEPTOR-BINDING; BRAIN; SIGMA(1); ATROPHY; SA4503; LIGAND;
D O I
10.1126/scitranslmed.abk1051
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cell stress and impaired oxidative phosphorylation are central to mechanisms of synaptic loss and neurodegeneration in the cellular pathology of Alzheimer's disease (AD). In this study, we quantified the in vivo expression of the endoplasmic reticulum stress marker, sigma 1 receptor (S1R), using [C-11]SA4503 positron emission tomography (PET), the mitochondrial complex I (MC1) with [F-18]BCPP-EF, and the presynaptic vesicular protein SV2A with [C-11]UCB-J in 12 patients with early AD and in 16 cognitively normal controls. We integrated these molecular measures with assessments of regional brain volumes and cerebral blood flow ( CBF) measured with magnetic resonance imaging arterial spin labeling. Eight patients with AD were followed longitudinally to estimate the rate of change of the physiological and structural pathology markers with disease progression. The patients showed widespread increases in S1R (<= 27%) and regional reduction in MC1 (>= -28%) and SV2A (>= -25%) radioligand binding, brain volume (>= -23%), and CBF (>= -26%). [F-18]BCPP-EF PET MC1 binding (>= -12%) and brain volumes (>= -5%) showed progressive reductions over 12 to 18 months, suggesting that they both could be used as pharmacodynamic indicators in early-stage therapeutics trials. Associations of reduced MC1 and SV2A and increased S1R radioligand binding with reduced cognitive performance in AD, although exploratory, suggested a loss of metabolic functional reserve with disease. Our study thus provides in vivo evidence for widespread, clinically relevant cellular stress and bioenergetic abnormalities in early AD.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Alzheimer's disease: A lesson from mitochondrial dysfunction
    Moreira, Paula I.
    Santos, Maria S.
    Oliveira, Catarina R.
    ANTIOXIDANTS & REDOX SIGNALING, 2007, 9 (10) : 1621 - 1630
  • [32] Axonal Transport and Mitochondrial Dysfunction in Alzheimer's Disease
    Riemer, Jan
    Kins, Stefan
    NEURODEGENERATIVE DISEASES, 2013, 12 (03) : 111 - 124
  • [33] Mitochondrial dysfunction and Alzheimer's disease: New developments
    Mancuso, Michelangelo
    Siciliano, Gabriele
    Filosto, Massimiliano
    Murri, Luigi
    JOURNAL OF ALZHEIMERS DISEASE, 2006, 9 (02) : 111 - 117
  • [34] Mitochondrial dysfunction and neuronal apoptosis in Alzheimer's disease
    Takuma, Kazuhiro
    Fukuzaki, Emiko
    Nagai, Taku
    Mizoguchi, Hiroyuki
    Stern, David M.
    Yan, Shirley ShiDu
    Yamada, Kiyofumi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2007, 103 : 45P - 45P
  • [35] Mitochondrial dysfunction and mitophagy failure in Alzheimer's disease
    Mary, Arnaud
    Vaillant-Beuchot, Loan
    Checler, Frederic
    Chami, Mounia
    M S-MEDECINE SCIENCES, 2021, 37 (10): : 843 - 847
  • [36] Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer's Disease
    Onukwufor, John O.
    Dirksen, Robert T.
    Wojtovich, Andrew P.
    ANTIOXIDANTS, 2022, 11 (04)
  • [37] Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future?
    Bell, Simon M.
    Barnes, Katy
    De Marco, Matteo
    Shaw, Pamela J.
    Ferraiuolo, Laura
    Blackburn, Daniel J.
    Venneri, Annalena
    Mortiboys, Heather
    BIOMEDICINES, 2021, 9 (01) : 1 - 26
  • [38] Mitochondrial dysfunction and cellularmetabolic deficiency in Alzheimer's disease
    Xue-Mei Gu 1
    Neuroscience Bulletin, 2012, 28 (05) : 631 - 640
  • [39] Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease
    Cai, Qian
    Tammineni, Prasad
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 57 (04) : 1087 - 1103
  • [40] The Association of Tau With Mitochondrial Dysfunction in Alzheimer's Disease
    Cheng, Ying
    Bai, Feng
    FRONTIERS IN NEUROSCIENCE, 2018, 12